Head and Neck Cancer
Protocol 221530 A Randomized, Double-blind, Placebo-controlled Phase 3 Study to evaluate Dostarlimab as Sequential Therapy after Chemoradiation in Participants with Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
- Details
ClinicalTrials.gov ID:
NCT06256588
Diagnosis Type:
NA
USOR Number:
- Address
,
P: